# EPCORE DLBCL-2 (NCT05578976)

> A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05578976
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genmab
- Conditions: Diffuse Large B-Cell Lymphoma
- Interventions: Epcoritamab; Cyclophosphamide; Rituximab; Vincristine; Doxorubicin; Prednisone
- Enrollment: 900
- Primary outcome: Number of Participants with Progression-Free Survival (PFS) with an International Prognostic Index (IPI) of 3-5

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 18
- YouTube: 4
- Podcasts: 1
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=epcore-dlbcl-2-nct05578976

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05578976", "email": "<work email>"}; the inbox owner confirms by the emailed link.